Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells(NIH)

N/A

Report date: 2023/04/06 20:00:19

Base Information

Drug NameAnti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells(NIH)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19Anti-CD20

TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, B-CellLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellLeukemia, Lymphocytic, Chronic, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A